Call +41-61-926-60-40 Fax +41-61-926-60-49

anti-Paraoxonase 1, mAb (17A12)

YIF-LF-MA0099 100 µl INQ
Actions
Select size:

* Required Fields

Amount:
Add to Cart
Call +41-61-926-60-40
Fax +41-61-926-60-49
Contact Us!
MSDS

Additional Information

Product Data
Synonyms PON; PON1; K-45; PON 1; EC=3.1.8.1; EC=3.1.1.2; EC=3.1.1.81; A-Esterase 1; Aromatic Esterase 1; Serum Aryldialkylphosphatase 1; Serum Paraoxonase/Arylesterase 1
Properties
Clone 17A12
Isotype Mouse IgG1 κ
Immunogen/Antigen Recombinant human His-PON1 protein purified E. coli.
Application Western Blot (1:500)
Crossreactivity Human, Mouse, Rat
Purity Detail Ammonium sulfate precipitation.
Formulation Liquid. HEPES with 0.15M NaCl, 0.01% BSA, 0.03% sodium azide, and 50% glycerol.
Other Product Data Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.
Origin Manufactured by AbFrontier
Product Type Monoclonal Antibody
Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage -20°C
Use/Stability Stable for at least 1 year after receipt when stored at -20°C.

Product Description

The paraoxonase(PON) gene-family in humans has three members, PON1, PON2, and PON3, aligned next to each other on the long arm of chromosome 7q21.3-22.1. PON1 of these is synthesized primarily in the liver and a portion is secreted into the plasma, where it is associated with high density lipoproteins (HDL). And It hydrolyzes the active metabolites of several other organophosphorus insecticides (e.g., chlorpyrifos oxon, diazoxon), as well as nerve agents such as sarin, soman and VX (lethal nerve agent). The PON1 polymorphism may be responsible for neurodegeneration and considered to be an independent risk factor for Parkinson’s disease. Hydrolyzes the toxic metabolites of a variety of organophosphorus insecticides. Capable of hydrolyzing a broad spectrum of organophosphate substrates and a number of aromatic carboxylic acid esters. May mediate an enzymatic protection of low density lipoproteins against oxidative modification and the consequent series of events leading to atheroma formation.

Product References

1) Akhmedova SN, et al. (2001) J Neurol Sci 184 (2):179-82. (General)
2) Kondo I, et al. (1998) Brain Res 806(2):271-3. (General)
No reviews for this product yet.